Skip to main content
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC — Investor Relations & Filings

Ticker · COLL ISIN · US19459J1043 LEI · 54930049FXZMTLW8D496 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2015-06-22 Interim / Quarterly Rep…
Country US United States of America
Listing US COLL

About COLLEGIUM PHARMACEUTICAL, INC

https://www.collegiumpharma.com/

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company that develops and commercializes medicines for people with serious medical conditions. The company is focused on building a portfolio of differentiated medications. Its primary area of expertise is in pain management, where it develops products with abuse-deterrent properties designed to be safer alternatives for patients and the community.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2015
2015-06-22 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 19, 2015, by Collegium Pharmaceutical, Inc. It contains detailed risk factors related to the company's financial position, capital needs, and business prospects. The text discusses the company's losses, lack of revenue, need for additional capital, and other operational risks. This type of disclosure is typical of a Current Report on Form 8-K, which is used to announce unscheduled material events or corporate changes that are important to shareholders. The document is not an annual or quarterly report, nor is it an earnings release or a proxy statement. It is not a certification or a short announcement but a substantive regulatory filing providing updated risk information. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-06-19 English
SCHEDULE 13D
Major Shareholding Notification
2015-05-21 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated May 14, 2015. The content focuses on adjustments to annual base salary and cash bonus eligibility for named executive officers, as well as stock option grants approved by the Board of Directors. This indicates changes in executive compensation and appointments. The key section is Item 5.02, which relates to departure, election, or appointment of directors or officers and compensatory arrangements. There is no financial report or earnings data, nor is this a proxy or voting result announcement. The document is not an annual or quarterly report, nor a legal proceeding or merger announcement. It clearly fits the category of Board/Management Information (MANG) because it announces changes related to senior management and their compensation.
2015-05-20 English
PRIMARY DOCUMENT
Director's Dealing
2015-05-19 English
PRIMARY DOCUMENT
Director's Dealing
2015-05-19 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.